Business Context and Reporting Period
This Form 6-K filing by IceCure Medical Ltd. covers the six-month period ended June 30, 2024. The report, filed on August 20, 2024, includes unaudited interim condensed consolidated financial statements, Management's Discussion and Analysis (MD&A), and a press release detailing operational performance.
Key Financial Metrics
The filing text provided is a cover page and table of contents; it does not contain the specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the attached exhibits (Exhibit 99.1 and 99.2) which are not included in the input text.
However, the press release title (Exhibit 99.3) explicitly states a 20% growth in ProSense® System and Probe sales for the first half of 2024.
Material Changes
- Sales Growth: The Company reported a 20% increase in ProSense® System and Probe sales compared to the prior comparable period.
- Market Adoption: The growth reflects continued adoption in the U.S. and other global markets.
Guidance, Outlook, and Risks
The provided text does not contain specific forward-looking guidance, detailed management commentary, risk factors, or contingencies beyond the headline sales growth. The full MD&A (Exhibit 99.2) and press release (Exhibit 99.3) would contain these details.
Investor Verification Checklist
- Verify the exact revenue and net loss figures for the six months ended June 30, 2024, in Exhibit 99.1.
- Confirm the cash balance and burn rate to assess liquidity runway in Exhibit 99.1.
- Review the breakdown of the 20% sales growth between the U.S. and international markets in Exhibit 99.3.
- Check for any updates on regulatory approvals or clinical trial milestones in the full MD&A (Exhibit 99.2).